After the Bell
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
Another crazy and profitable year in biotech investing was captured 140 characters at a time.
One biotech CEO won accolades in 2010 only to be razzed for poor performance in 2011.
The CEOs of Aegerion, Dendron, CytRx, Galena, Repros, Northwest Bio and Retrophin deserve jeers for their performances this year, but who's the worst of the bunch?
A new form of cancer immunotherapy known as CAR-T promises to radically change the way certain blood cancers are treated.
©1996-2016 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.